Danaher Co. (NYSE:DHR) Shares Purchased by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC raised its position in Danaher Co. (NYSE:DHR) by 5.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,637 shares of the conglomerate’s stock after acquiring an additional 82 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Danaher were worth $455,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher in the second quarter valued at $25,000. Redmont Wealth Advisors LLC purchased a new position in Danaher in the first quarter valued at $30,000. MFA Wealth Advisors LLC acquired a new position in Danaher during the 2nd quarter worth $51,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher during the 2nd quarter worth about $51,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DHR has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday. Raymond James dropped their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday. Bank of America lifted their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, UBS Group decreased their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by insiders.

Danaher Trading Down 1.0 %

NYSE DHR opened at $245.41 on Friday. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The firm has a market cap of $181.77 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. The firm’s fifty day moving average is $270.00 and its two-hundred day moving average is $260.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business earned $2.02 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year. Analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.